Skip to main content

Table 4 Interaction effects analysis for the Week 12 and Week 52 predictor models

From: Predictors of long-term clinical response in patients with non-radiographic axial spondyloarthritis receiving certolizumab pegol

  Week 12 Week 52
Interaction effect ASDAS-MI ASAS40 BASDAI50 ASDAS-ID ASDAS-MI ASAS40 BASDAI50 ASDAS-ID
MRI*HLA-B27 0.5599 0.8460 0.1517 0.6183 0.0035* 0.0014* 0.0049* 0.0247*
Sex*MRI 0.6680 0.3600 0.6663 0.9666 0.0005* 0.9107 0.1873 0.0030*
Age*MRI 0.8676 0.5666 0.0916 0.2039 0.9140 0.8291 0.4061 0.7247
CRP*MRI 0.8584 0.4112 0.7003 0.0681 0.0626 0.7511 0.7955 0.4636
Sex*CRP 0.7179 0.3568 0.5063 0.8552 0.8904 0.7033 0.6215 0.2282
Age*CRP 0.9958 0.4325 0.0985 0.5441 0.0526 0.3986 0.9907 0.3007
  1. p-values from the final regression step are reported. *Significant interaction terms included in the final model. ASAS40 Assessment of SpondyloArthritis International Society 40%, ASDAS Ankylosing Spondylitis Disease Activity Score, ASDAS-ID ASDAS inactive disease (ASDAS <1.3), ASDAS-MI ASDAS major improvement (reduction in ASDAS ≥2.0), BASDAI50 Bath Ankylosing Spondylitis Disease Activity Index 50%, HLA-B27 human leukocyte antigen-B27, MRI magnetic resonance imaging